Observational studyF1000Research2025
Longitudinal Assessment of Neurocognitive Outcomes and Correlation with Limbic System Radiation Doses in Patients Undergoing Radiotherapy for Central Nervous System Tumours: A preliminary report.
Observational study in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiation therapy (RT) for central nervous system (CNS) malignancies can result in neurocognitive decline, affecting quality of life. While hippocampal-sparing approaches are well documented, limited data exist on the impact of radiation dose to other cognitive structures. This prospective study evaluates domain-specific cognitive changes following RT and explores correlations with radiation dose to key brain regions. Methodology: Twenty-five patients with primary CNS tumours undergoing focal radiotherapy, with or without concurrent chemotherapy, were enrolled. Neurocognitive function was assessed using the Addenbrooke's Cognitive Examination III (ACE-III) tool, pre- and six months post-treatment. Radiation dose-volume histogram (DVH) data were analyzed for structures including the hippocampus, amygdala, cerebellum, and corpus callosum. Patients were stratified based on ACE-III score decline (≥3 points vs. <3 points), and dose-response correlations were examined. Results: A statistically significant decline in mean ACE-III scores was observed post-treatment (pre: 89.48 ± 6.84 vs. post: 87.91 ± 6.29, p = 0.007). Attention, language, and fluency were the most affected domains. Patients with cognitive decline received higher radiation doses to all examined structures, with the corpus callosum showing the strongest association (mean dose in decline group: 35.91 Gy vs. 30.70 Gy; p = 0.440). However, no dose-response relationship reached statistical significance. Conclusion: This study highlights early, domain-specific neurocognitive decline following focal RT for CNS tumours, with attention and language being most vulnerable. Corpus callosum dose emerged as a key correlate. These findings suggest the need to broaden neuroprotection strategies beyond the hippocampus and emphasize the value of incorporating routine neurocognitive assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.